Takeda Pharmaceutical
TAK
313 hedge funds and large institutions have $1.76B invested in Takeda Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 87 increasing their positions, 101 reducing their positions, and 59 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
0.89% less ownership
Funds ownership: 8.24% → 7.35% (-0.89%)
8% less funds holding
Funds holding: 339 → 313 (-26)
14% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 101
16% less call options, than puts
Call options by funds: $46.4M | Put options by funds: $54.9M
30% less capital invested
Capital invested by funds: $2.53B → $1.76B (-$770M)
36% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$31.8M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$31.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.4M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$24M |
| 5 |
Morgan Stanley
New York
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$193M |
| 2 |
MAM
Melqart Asset Management
London,
United Kingdom
|
-$30.7M |
| 3 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
-$22.8M |
| 4 |
Goldman Sachs
New York
|
-$22.2M |
| 5 |
TAL
TIG Advisors LLC
New York
|
-$21.2M |
TAK Hedge Fund Activity: Q1 2020 in Review
313 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2020, worth a combined $1.76B — down 30% from $2.53B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of TAK and 38 opened new positions — a net loss of 21 holders — while 101 trimmed existing stakes and 87 added.
The largest buyer was Renaissance Technologies, adding an estimated $31.8M. The largest seller was Glenview Capital Management, cutting an estimated $193M.
- 313 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2020, down from 339 in Q4 2019.
- Funds reported $1.76B of Takeda Pharmaceutical stock for Q1 2020, down 30% quarter-over-quarter.
- 38 funds opened new Takeda Pharmaceutical positions in Q1 2020 and 59 closed out, a net change of -21 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2020 was Renaissance Technologies, an estimated $31.8M added.
- The largest Takeda Pharmaceutical seller in Q1 2020 was Glenview Capital Management, an estimated $193M sold.
Based on aggregated 13F filings for Q1 2020.